资讯
内科
心血管
肿瘤
内分泌
普通内科
消化
呼吸
神经科
传染科
精神心理
肾内科
风湿免疫
血液科
老年医学
外科
头颈外科
胃肠外科
血管外科
肝胆胰外
骨科
普通外科
胸心外科
神经外科
泌尿外科
烧伤科
整形美容
麻醉疼痛
专科科室
罕见病
康复医学
药械
儿科
耳鼻咽喉
口腔科
眼科
政策人文
营养全科
预防公卫
妇产科
中医科
急重症
皮肤性病
影像放射
转化医学
检验病理
护理
热点
临床研究
研究设计
人工智能
智慧医疗
论文基金
医学科普
药物经济
医生集团
职业安全
患者招募
医学科研
公司产业
医学英语
MedSci动态
指南
按科室浏览
肿瘤科
心血管
传染科
妇产科
神经科
儿科
呼吸
内分泌科
血液科
消化
更多科室
工具
临床工具
临床指南
医学计算与公式
ICD-10/ICD-11疾病编码
医讯达
直播
话题
公开课
精品课
科研工具
期刊数据库查询
期刊智能选择
全球基金查询
文献查询
SCI写作宝典
生物医药大词典
其他工具
下载App使用方便更快捷
Medsci 梅斯搜索
公开课
精品课
服务
科研数智化
直播,公开课与精品课
科研加速器
研究者发起的临床研究(IIS)支持
真实世界研究解决方案
药物经济学
医保准入事务
研究方案设计
数据库建立与管理
药物警戒(PV)
真实世界研究执行
数据统计分析
数字化学术传播解决方案
多渠道营销(MCM)
产品医学策略
学术传播(APO)
其它
积分商城
FAQS
#适应症#
219篇内容 | 3004人围观
关注话题
话题活跃用户
#
插入话题
插入图片
评论
最新
最热
GetTopicDetailResponse(id=554d94e13ae, topicName=适应症, introduction=适应症, content=null, image=null, comments=219, allHits=3004, url=https://h5.medsci.cn/topic?id=94713, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=11412, tagList=[TagDto(tagId=11412, tagName=适应症)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1336708, encodeId=07e01336e086c, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=腺样体切除术-手术适应症(图片), objectType=article, longId=59772, objectId=47d759e72d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47d759e72d6, replyNumber=0, likeNumber=97, createdTime=2015-12-02, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47d759e72d6, moduleTitle=腺样体切除术-手术适应症(图片), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47d759e72d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336709, encodeId=e8c91336e0910, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=颅面重建术手术-适应症(图片), objectType=article, longId=59776, objectId=2d3559e762e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d3559e762e, replyNumber=0, likeNumber=51, createdTime=2015-12-02, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d3559e762e, moduleTitle=颅面重建术手术-适应症(图片), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d3559e762e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336700, encodeId=68c01336e00ba, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=拜耳眼科药物Eylea视网膜静脉阻塞继发黄斑水肿(ME-RVO)新适应症获日本批准, objectType=article, longId=52572, objectId=bff4525e2dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bff4525e2dc, replyNumber=0, likeNumber=78, createdTime=2015-07-01, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bff4525e2dc, moduleTitle=拜耳眼科药物Eylea视网膜静脉阻塞继发黄斑水肿(ME-RVO)新适应症获日本批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bff4525e2dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336699, encodeId=38f2133669973, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=强生突破性抗癌药Imbruvica第4个适应症获欧盟CHMP支持, objectType=article, longId=51482, objectId=da2851482b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da2851482b4, replyNumber=0, likeNumber=92, createdTime=2015-06-03, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da2851482b4, moduleTitle=强生突破性抗癌药Imbruvica第4个适应症获欧盟CHMP支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da2851482b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336698, encodeId=95df133669870, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=诺华重磅药物Jakavi欧盟收获新适应症:真性红细胞增多症(PV), objectType=article, longId=48434, objectId=d5af48434cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5af48434cb, replyNumber=0, likeNumber=79, createdTime=2015-03-22, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5af48434cb, moduleTitle=诺华重磅药物Jakavi欧盟收获新适应症:真性红细胞增多症(PV), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5af48434cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336697, encodeId=8e2c133669e48, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=后生可畏,拜耳眼科药物Eylea第4个适应症获欧盟批准, objectType=article, longId=47529, objectId=cb1f4e529ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb1f4e529ab, replyNumber=0, likeNumber=71, createdTime=2015-03-02, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb1f4e529ab, moduleTitle=后生可畏,拜耳眼科药物Eylea第4个适应症获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb1f4e529ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336696, encodeId=9a6d13366960b, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=PD-1市场硝烟再起,默沙东将向FDA提交Keytruda肺癌适应症审批申请, objectType=article, longId=45445, objectId=c4f34544526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4f34544526, replyNumber=0, likeNumber=53, createdTime=2015-01-16, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4f34544526, moduleTitle=PD-1市场硝烟再起,默沙东将向FDA提交Keytruda肺癌适应症审批申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4f34544526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336695, encodeId=032213366951e, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=拜耳造影剂Gadavist新适应症获FDA批准,用于两周岁以下患儿, objectType=article, longId=45126, objectId=e0a5451262d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0a5451262d, replyNumber=0, likeNumber=69, createdTime=2015-01-09, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0a5451262d, moduleTitle=拜耳造影剂Gadavist新适应症获FDA批准,用于两周岁以下患儿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0a5451262d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336694, encodeId=7d6e133669494, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=诺华青光眼药物Travatan(曲伏前列素滴眼液)收获欧盟儿科适应症, objectType=article, longId=44608, objectId=d43d44608a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d43d44608a2, replyNumber=0, likeNumber=50, createdTime=2014-12-27, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d43d44608a2, moduleTitle=诺华青光眼药物Travatan(曲伏前列素滴眼液)收获欧盟儿科适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d43d44608a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336693, encodeId=f788133669332, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA批准礼来单抗Cyramza第3个适应症:非小细胞肺癌, objectType=article, longId=44300, objectId=82284430006, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82284430006, replyNumber=0, likeNumber=73, createdTime=2014-12-21, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82284430006, moduleTitle=FDA批准礼来单抗Cyramza第3个适应症:非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82284430006)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336692, encodeId=f88213366925a, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=COA 2014:严格掌握颈前路融合与非融合手术联合应用适应症, objectType=article, longId=43252, objectId=ccd743252ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccd743252ae, replyNumber=0, likeNumber=56, createdTime=2014-11-29, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccd743252ae, moduleTitle=COA 2014:严格掌握颈前路融合与非融合手术联合应用适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccd743252ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336691, encodeId=3a89133669127, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=球No.1添第8个适应症——FDA批准Humira用于儿科克罗恩病患者, objectType=article, longId=40761, objectId=e29840e61f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e29840e61f7, replyNumber=0, likeNumber=76, createdTime=2014-09-30, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e29840e61f7, moduleTitle=球No.1添第8个适应症——FDA批准Humira用于儿科克罗恩病患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e29840e61f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336690, encodeId=77e81336690db, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA批准葛兰素史克Promacta新适应症, objectType=article, longId=39711, objectId=32dd39e1102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32dd39e1102, replyNumber=0, likeNumber=66, createdTime=2014-08-30, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32dd39e1102, moduleTitle=FDA批准葛兰素史克Promacta新适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32dd39e1102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336689, encodeId=0145133668975, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=阿瓦斯汀铂类耐药复发性卵巢癌新适应症获欧盟批准, objectType=article, longId=38954, objectId=3ffd3895492, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ffd3895492, replyNumber=0, likeNumber=0, createdTime=2014-08-13, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ffd3895492, moduleTitle=阿瓦斯汀铂类耐药复发性卵巢癌新适应症获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ffd3895492)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336688, encodeId=f031133668894, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=罗氏贝伐单抗新适应症获美国FDA快速审批, objectType=article, longId=37979, objectId=37d13e979bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37d13e979bc, replyNumber=0, likeNumber=79, createdTime=2014-07-20, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37d13e979bc, moduleTitle=罗氏贝伐单抗新适应症获美国FDA快速审批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37d13e979bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336687, encodeId=534b133668ee2, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=拜耳多吉美(Nexavar)甲状腺癌新适应症获日本批准, objectType=article, longId=36875, objectId=dbda368e5c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbda368e5c8, replyNumber=0, likeNumber=72, createdTime=2014-06-25, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbda368e5c8, moduleTitle=拜耳多吉美(Nexavar)甲状腺癌新适应症获日本批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbda368e5c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336686, encodeId=9b781336686ee, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=勃林格殷格翰抗凝血剂Pradaxa新适应症获FDA批准, objectType=article, longId=33005, objectId=a40633005e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a40633005e5, replyNumber=0, likeNumber=72, createdTime=2014-04-10, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a40633005e5, moduleTitle=勃林格殷格翰抗凝血剂Pradaxa新适应症获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a40633005e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336685, encodeId=bfde13366854b, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=诺华单抗药索雷尔(Xolair)新适应症获欧盟批准, objectType=article, longId=31628, objectId=44263162852, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44263162852, replyNumber=0, likeNumber=70, createdTime=2014-03-09, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44263162852, moduleTitle=诺华单抗药索雷尔(Xolair)新适应症获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44263162852)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336684, encodeId=d627133668405, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=拜耳在日本提交Eylea DME新适应症申请, objectType=article, longId=31468, objectId=9003314688f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9003314688f, replyNumber=0, likeNumber=65, createdTime=2014-03-06, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9003314688f, moduleTitle=拜耳在日本提交Eylea DME新适应症申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9003314688f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336683, encodeId=ff88133668322, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=强生拜瑞妥(Xarelto)ACS适应症遭FDA拒绝, objectType=article, longId=30710, objectId=226d30e1046, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=226d30e1046, replyNumber=0, likeNumber=69, createdTime=2014-02-19, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=226d30e1046, moduleTitle=强生拜瑞妥(Xarelto)ACS适应症遭FDA拒绝, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=226d30e1046)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯话题小助手
关注
已关注
适应症
2020-05-29
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
腺样体切除术-手术适应症(图片)
97
0
2015-12-02
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
颅面重建术手术-适应症(图片)
51
0
2015-12-02
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
拜耳眼科药物Eylea视网膜静脉阻塞继发黄斑水肿(ME-RVO)新适应症获日本批准
78
0
2015-07-01
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
强生突破性抗癌药Imbruvica第4个适应症获欧盟CHMP支持
92
0
2015-06-03
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
诺华重磅药物Jakavi欧盟收获新适应症:真性红细胞增多症(PV)
79
0
2015-03-22
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
后生可畏,拜耳眼科药物Eylea第4个适应症获欧盟批准
71
0
2015-03-02
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
PD-1市场硝烟再起,默沙东将向FDA提交Keytruda肺癌适应症审批申请
53
0
2015-01-16
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
拜耳造影剂Gadavist新适应症获FDA批准,用于两周岁以下患儿
69
0
2015-01-09
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
诺华青光眼药物Travatan(曲伏前列素滴眼液)收获欧盟儿科适应症
50
0
2014-12-27
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
FDA批准礼来单抗Cyramza第3个适应症:非小细胞肺癌
73
0
2014-12-21
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
COA 2014:严格掌握颈前路融合与非融合手术联合应用适应症
56
0
2014-11-29
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
球No.1添第8个适应症——FDA批准Humira用于儿科克罗恩病患者
76
0
2014-09-30
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
FDA批准葛兰素史克Promacta新适应症
66
0
2014-08-30
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
阿瓦斯汀铂类耐药复发性卵巢癌新适应症获欧盟批准
0
0
2014-08-13
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
罗氏贝伐单抗新适应症获美国FDA快速审批
79
0
2014-07-20
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
拜耳多吉美(Nexavar)甲状腺癌新适应症获日本批准
72
0
2014-06-25
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
勃林格殷格翰抗凝血剂Pradaxa新适应症获FDA批准
72
0
2014-04-10
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
诺华单抗药索雷尔(Xolair)新适应症获欧盟批准
70
0
2014-03-09
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
拜耳在日本提交Eylea DME新适应症申请
65
0
2014-03-06
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
强生拜瑞妥(Xarelto)ACS适应症遭FDA拒绝
69
0
2014-02-19
回复
共220条
首页
上一页
下一页
尾页
页码:
10
/11页
20条/页
扫描二维码下载梅斯医学APP
科室
订阅+
更多科室
工具
服务